Company: JUNS
Filing Date: 2025-11-06
Form Type: DEF 14A
Source: 0001493152-25-020988
Chunk: 35

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-06
Form: DEF 14A
Chunk 35
---
 | -12 |     |            |       - |     |           | - |     |                  | 146,602 |     |                      | 363,481 |     |                                             |   |     |                                                   |   |     |                            | 35,000 | -13 |     |           |   545,083 |

| (1) | Amounts                                                                                     
 reflect the aggregate grant-date fair value of stock awards computed in accordance with the 
 Financial Accounting Standards Board’s Accounting Standards Codification Topic 718.         
 See Note 6 – Stockholders’ Equity (Deficit) – Stock Options.                                |
| (2) | Includes                                                                                    
 healthcare benefits and 401(k) contribution of $19,326 and $0, respectively, for the fiscal 
 year ended December 31, 2024.                                                               |
| (3) | During                                                                                      
 2023, Mr. Rosén’s salary was deferred and effective October 1, 2023 was reduced             
 to $84,000. The deferred compensation is recorded in accrued compensation as of December    
 31, 2023. No interest was accrued or due on the deferred compensation for 2023.             |

On September 29, 2023, Mr. Rosén received 710,344 options to purchase common stock, 430,181 restricted stock units, which were reissued with additional options to purchase 88,090 shares of common stock and an additional 67,215 restricted stock units. The options to purchase common stock have a strike price of $1.33.

| (4) | Includes                                                                                   
 healthcare benefits and 401(k) contribution of $4,286 and $0, respectively, for the fiscal 
 year ended December 31, 2023.                                                              |

| -19- |

| (5) | During                                                                                                                                
 2023, Mr. Elmasri’s, through his consulting company Titan Advisory Services, LLC (“Titan”), salary compensation                       
 was deferred and effective February 1, 2023 was reduced to $250,000, and was further reduced effective October 1, 2023 to $60,000.    
 The deferred compensation is recorded in accrued compensation as of December 31, 2023. No interest was accrued or due on the deferred 
 compensation for 2023. Mr. Elmasri and his wife are the only shareholders of Titan.                                                   |

On September 29, 2023, Mr. Elmasri, on behalf of Titan, received